EXHIBIT 1

In The Matter Of:

v.
MEDICIS AESTHETICS, INC.

WELDON, RYAN - Vol. 1
January 13, 2015

CONFIDENTIAL

MERRILL CORPORATION

LegaLink, Inc.

20750 Ventura Boulevard Suite 205 Woodland Hills, CA 91364 Phone: 818.593.2300 Fax: 818.593.2301

Page 1

UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA
-----X
ALLERGAN USA, INC., and ALLERGAN
INDUSTRIE, SAS,

Plaintiffs,

-against-

Case No.
SACV13-01436 AG
(JPRx)

MEDICIS AESTHETICS, INC.,
MEDICIS PHARMACEUTICAL CORP.,
VALEANT PHARMACEUTICALS
NORTH AMERICA LLC,
VALEANT PHARMACEUTICALS
INTERNATIONAL, and VALEANT
PHARMACEUTICALS INTERNATIONAL, INC.

Defendants.

-----x CONFIDENTIAL

January 13, 2015 9:02 a.m.

Videotaped Deposition of RYAN WELDON taken by Plaintiff, pursuant to Notice, at the offices of Patterson Belknap Webb & Tyler LLP, 1133

Avenue of the Americas, New York, New York, before TAMMEY M. PASTOR, a Registered

Professional Reporter, Certified LiveNote

Reporter and Notary Public within and for the State of New York.

Merrill Corporation

Page 2

		rage z
1	APPEARANCES:	
2	FISH & RICHARDSON P.C. Attorneys for Plaintiffs	
3	222 Delaware Avenue, 17th Floor	
4	P.O. Box 1114	
5	Wilmington, DE 19801	
	BY: SUSAN MORRISON COLETTI, ESQ.	
6	(coletti@fr.com)	
7		
8	PATTERSON BELKNAP WEBB & TYLER LLP	
9	Attorneys for Defendants	
10	1133 Avenue of the Americas New York, NY 10036-6710	
11	BY: SCOTT B. HOWARD, ESQ.	
	(Sbhoward@pbwt.com)	
12		
13	ALSO PRESENT:	
14	DAVID PELOZA, Videographer Merrill Legal Solutions	
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		

Merrill Corporation

800-826-0277

1	stimulator of your body's collagen.	10:04:31
2	So you have four categories.	10:04:37
3	This actually encompasses the full portfolio	10:04:42
4	for aesthetics post acquisition of Medicis	10:04:44
5	for the company. And we felt, you know, we	10:04:49
6	would have offerings in each of these. And	10:04:51
7	these are all used within an aesthetics	10:04:54
8	office. So that's why they were	10:04:56
9	complementary.	10:04:57
10	Q. Can you go to 21 now. On the	10:05:05
11	right side the first bullet point says,	10:05:15
12	"Significant majority of synergies to come	10:05:18
13	from head count reduction."	10:05:21
14	Do you see that?	10:05:23
15	A. Yes.	10:05:23
16	Q. What does that mean?	10:05:24
17	A. So when we would assess deals	10:05:25
18	you're trying to extract synergies, there	10:05:32
19	would be cost synergies, then there is	10:05:34
20	revenue synergies. So how would the	10:05:37
21	combination of the companies help to	10:05:41
22	increase the top line or reduce costs.	10:05:43
23	In reducing costs obviously	10:05:47
24	there is a lot of opportunities, you can	10:05:51
25	spend less money on advertising or, you	10:05:55

1	know, those type of things.	10:05:57
2	In this particular deal there	10:05:59
3	was a lot of overlap in terms of corporate	10:06:02
4	structure corporate staff. Medicis which	10:06:04
5	was headquarters in Scottsdale, Arizona had	10:06:08
6	a large sort of headquarter based, large	10:06:11
7	number of personnel there.	10:06:18
8	Many of the positions were	10:06:20
9	duplicative with the positions that we had	10:06:23
10	in New Jersey. So, you know, for one company	10:06:26
11	you no longer need two heads of investor	10:06:29
12	relations, you only need one.	10:06:32
13	So there were quite a few sort	10:06:33
14	of overlaps. There were some areas where we	10:06:37
15	didn't overlap. But the largest number of	10:06:42
16	the synergies, in terms of cost reductions	10:06:44
17	was really going to come from those overlaps	10:06:46
18	and reducing personnel.	10:06:49
19	In some cases eliminating	10:06:51
20	positions in the New Jersey office and in	10:06:53
21	other situations reducing the personnel and	10:06:57
22	head count at the Medicis office in Arizona.	10:07:00
23	Q. Do you have any sense of how	10:07:04
24	many people were let go after the Medicis	10:07:05
25	acquisition?	10:07:08
1		

CONFIDENTIAL RYAN WELDON - 1/13/2015

Page 58

		1
1	A. Yes. In Arizona it was about	10:07:09
2	300, 320.	10:07:13
3	Q. Out of how many employees were	10:07:15
4	there?	10:07:16
5	A. Maybe 520. 500, around there.	10:07:16
6	Q. How many were let go in New	10:07:21
7	Jersey?	10:07:23
8	A. I do not recall that. That	10:07:23
9	would have mostly been I believe on the	10:07:28
10	clinical side and I was not too closely	10:07:32
11	involved with which clinical positions were	10:07:35
12	where.	10:07:38
13	I know that there was, there	10:07:38
14	were a number of people from the clinical	10:07:41
15	from Medicis's clinical team that were	10:07:43
16	retained in Arizona. They eventually left on	10:07:46
17	their own for the most part. But they had	10:07:49
18	more dermatology expertise.	10:07:53
19	When we bought Dermik and Ortho	10:07:55
20	Derm from Sanofi Aventis and J&J	10:07:58
21	respectively, we got sales forces. We	10:08:02
22	didn't get a bunch of clinical people with	10:08:05
23	expertise in those areas. So Medicis was the	10:08:06
24	first acquisition where we really got people	10:08:09
25	that had a lot of dermatology experience.	10:08:11

Merrill Corporation

800-826-0277

1	Some of our people in New Jersey had that.	10:08:15
2	But how those sort of fell out I can't	10:08:17
3	3 recall.	10:08:21
4	Q. By the time you left Valeant	10:08:26
5	how many of those legacy Medicis employees	10:08:29
6	were still around?	10:08:32
7	A. Excluding the sales force?	10:08:32
8	Q. Uh-huh.	10:08:34
9	A. Very few. In aesthetics Vince	10:08:35
10	had been there remained there until	10:08:44
11	almost the end of 2013. A couple of other	10:08:47
12	people on that team stayed until October	10:08:51
13	when we decided to move. We actually made	10:08:54
14	the decision to move to shut down	10:08:57
15	Arizona, that headquarters a month after I	10:09:02
16	moved there in maybe the September 2013,	10:09:04
17	around that September time frame.	10:09:10
18	So at that point there were a	10:09:13
19	number of people that were offered	10:09:14
20	opportunity to move to New Jersey, which	10:09:16
21	apparently is a hard sell coming from	10:09:18
22	Arizona. Some people chose not to take that	10:09:20
23	3 opportunity.	10:09:23
24	So we ended up letting go of	10:09:26
25	some people that in Scottsdale. But I	10:09:29

1	would say for the most part most of	10:09:32
2	the people in the Scottsdale office, within	10:09:36
3	ten months were gone.	10:09:38
4	MR. HOWARD: We have been going	10:09:42
5	over an hour, whenever it is a good time	10:09:43
6	for a break.	10:09:46
7	MS. COLETTI: I was just about to	10:09:46
8	say why don't we take a quick break.	10:09:47
9	THE VIDEOGRAPHER: Okay. We	10:09:49
10	will go off the record. The time is	10:09:50
11	10:09.	10:09:52
12	(Recess taken.)	10:09:59
13	THE VIDEOGRAPHER: Back on the	10:21:19
14	record 10:21.	10:21:28
15	EXAMINATION CONDUCTED BY	10:21:30
16	MS. COLETTI:	10:21:30
17	Q. Welcome back, Mr. Weldon. I	10:21:30
18	want to talk a little bit about some of the	10:21:34
19	other acquisitions. In particular, were you	10:21:37
20	involved at all in the potential acquisition	10:21:40
21	of Allergan?	10:21:42
22	A. How would you define involved?	10:21:45
23	Q. Did you do any evaluations, did	10:21:46
24	you look at any documents?	10:21:48
25	A. By that definition, I had very,	10:21:52